Literature DB >> 10756006

Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: a tool to study the fine specificity of the antiviral response.

C Retière1, V Prod'homme, B M Imbert-Marcille, M Bonneville, H Vié, M M Hallet.   

Abstract

Cytotoxic T lymphocytes (CTLs) play a central role in the control of persistent human cytomegalovirus (HCMV) infection in healthy virus carriers. Previous analyses of the specificity of HCMV-reactive CD8(+) CTLs drawn from in vitro models in which antigen-presenting cells were autologous fibroblasts infected with laboratory HCMV strains have shown focusing of CTL responses against the major tegument protein, pp65. By contrast, the 72-kDa major immediate-early protein (IE1) was identified as a minor target for this response. Here we have studied the fine specificity and T-cell-receptor features of T-cell clones generated against autologous B lymphoblastoid cell lines stably transfected with HCMV cDNA coding for either pp65 or a natural variant of IE1. This strategy allowed efficient generation of T-cell clones against IE1 and pp65 and led to the identification of several new IE1 and pp65 epitopes, including some located in polymorphic regions of IE1. Such an approach may provide relevant information about the characteristics of the CTL response to IE1 and the effect of viral polymorphism on the immune response against HCMV.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10756006      PMCID: PMC111908          DOI: 10.1128/jvi.74.9.3948-3952.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

Review 1.  Therapeutic reconstitution of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones.

Authors:  S R Riddell; P D Greenberg
Journal:  Curr Top Microbiol Immunol       Date:  1994       Impact factor: 4.291

2.  Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes.

Authors:  E McLaughlin-Taylor; H Pande; S J Forman; B Tanamachi; C R Li; J A Zaia; P D Greenberg; S R Riddell
Journal:  J Med Virol       Date:  1994-05       Impact factor: 2.327

3.  Human cytomegalovirus latent infection of granulocyte-macrophage progenitors.

Authors:  K Kondo; H Kaneshima; E S Mocarski
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

4.  Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited.

Authors:  F Kern; I P Surel; N Faulhaber; C Frömmel; J Schneider-Mergener; C Schönemann; P Reinke; H D Volk
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

5.  Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains.

Authors:  M F Beersma; M J Bijlmakers; H L Ploegh
Journal:  J Immunol       Date:  1993-11-01       Impact factor: 5.422

6.  Locus-specific amplification of HLA class I genes from genomic DNA: locus-specific sequences in the first and third introns of HLA-A, -B, and -C alleles.

Authors:  N Cereb; P Maye; S Lee; Y Kong; S Y Yang
Journal:  Tissue Antigens       Date:  1995-01

7.  Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains.

Authors:  T R Jones; L K Hanson; L Sun; J S Slater; R M Stenberg; A E Campbell
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

8.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.

Authors:  E A Walter; P D Greenberg; M J Gilbert; R J Finch; K S Watanabe; E D Thomas; S R Riddell
Journal:  N Engl J Med       Date:  1995-10-19       Impact factor: 91.245

9.  Induction of endogenous human cytomegalovirus gene expression after differentiation of monocytes from healthy carriers.

Authors:  J Taylor-Wiedeman; P Sissons; J Sinclair
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Surface expression of functional T cell receptor chains formed by interlocus recombination on human T lymphocytes.

Authors:  F Davodeau; M A Peyrat; J Gaschet; M M Hallet; F Triebel; H Vié; D Kabelitz; M Bonneville
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

View more
  19 in total

1.  Cross-reactivity of HLA-B*1801-restricted T-lymphocyte clones with target cells expressing variants of the human cytomegalovirus 72kDa-IE1 protein.

Authors:  Virginie Prod'homme; Christelle Retière; Ralitza Valtcheva; Marc Bonneville; Marie-Martine Hallet
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

2.  Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response.

Authors:  Ghislaine Gallez-Hawkins; Maria C Villacres; Xiuli Li; Margaret C Sanborn; Norma A Lomeli; John A Zaia
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

3.  Persistent viral infection in humans can drive high frequency low-affinity T-cell expansions.

Authors:  Naeem Khan; Mark Cobbold; Joanne Cummerson; Paul A H Moss
Journal:  Immunology       Date:  2010-08-16       Impact factor: 7.397

4.  Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T cell repertoire.

Authors:  Ryan O Emerson; William S DeWitt; Marissa Vignali; Jenna Gravley; Joyce K Hu; Edward J Osborne; Cindy Desmarais; Mark Klinger; Christopher S Carlson; John A Hansen; Mark Rieder; Harlan S Robins
Journal:  Nat Genet       Date:  2017-04-03       Impact factor: 38.330

5.  Ex vivo stimulation and expansion of both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65.

Authors:  J Vaz-Santiago; J Lulé; P Rohrlich; C Jacquier; N Gibert; E Le Roy; D Betbeder; J L Davignon; C Davrinche
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  Selection of Epstein-Barr virus specific cytotoxic T lymphocytes can be performed with B lymphoblastoid cell lines created in serum-free media.

Authors:  G Gallot; S Vollant; R Vivien; B Clémenceau; C Ferrand; P Tiberghien; J Gaschet; N Robillard; H Vié
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

7.  Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers.

Authors:  Rebecca Elkington; Susan Walker; Tania Crough; Moira Menzies; Judy Tellam; Mandvi Bharadwaj; Rajiv Khanna
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

8.  Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness.

Authors:  Prasanna Jagannathan; Christine M Osborne; Cassandra Royce; Maura M Manion; John C Tilton; Li Li; Steven Fischer; Claire W Hallahan; Julia A Metcalf; Mary McLaughlin; Matthew Pipeling; John F McDyer; Thomas J Manley; Jeffery L Meier; John D Altman; Laura Hertel; Richard T Davey; Mark Connors; Stephen A Migueles
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

9.  Refinement of strategies for the development of a human cytomegalovirus dense body vaccine.

Authors:  Véronique Mersseman; Verena Böhm; Rafaela Holtappels; Petra Deegen; Uwe Wolfrum; Bodo Plachter; Sabine Reyda
Journal:  Med Microbiol Immunol       Date:  2008-03-05       Impact factor: 3.402

10.  Mature CD8(+) T lymphocyte response to viral infection during fetal life.

Authors:  Arnaud Marchant; Victor Appay; Marianne Van Der Sande; Nicolas Dulphy; Corinne Liesnard; Michael Kidd; Steve Kaye; Olubukola Ojuola; Geraldine M A Gillespie; Ana L Vargas Cuero; Vincenzo Cerundolo; Margaret Callan; Keith P W J McAdam; Sarah L Rowland-Jones; Catherine Donner; Andrew J McMichael; Hilton Whittle
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.